Bankrupt Biotech Targets Nixon Peabody, Mintz Levin
Neogenix Oncology Inc., a bankrupt would-be developer of cancer diagnostic and treatment products, blamed its outside lawyers for allowing the company to pursue an illegal fund-raising strategy for more than five years.
This premium content is reserved for American Lawyer subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now